COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 DKK | +0.07% | +1.16% | +26.51% |
May. 09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
May. 09 | News Highlights : Top Company News of the Day - Thursday at 1 PM ET | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
883.2 DKK | +0.07% | +1.16% | 568B | ||
55.98 USD | -0.39% | -0.64% | 10.13B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.51% | 568B | |
+32.36% | 695B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.91% | 239B | |
+8.14% | 204B | |
-7.69% | 198B | |
+8.62% | 168B | |
+4.48% | 125B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk owner refiles U.S. application for approval of Catalent deal